ACRV - Company ID 0001781174
The table below shows Acrivon Therapeutics, Inc.'s balance sheet line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & equivalents | $41.50M | $39.82M | $36.02M | $29.52M |
| Short-term investments | $77.08M | $139.66M | $91.44M | $98.23M |
| Receivables | - | - | - | - |
| Inventory | - | - | - | - |
| Total current assets | $120.44M | $181.63M | $129.69M | $132.09M |
| Property, plant & equipment | $4.89M | $4.47M | $3.48M | $2.09M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Goodwill | - | - | - | - |
| Total assets | $129.72M | $196.59M | $138.26M | $181.23M |
| Accounts payable | $2.28M | $758.00K | $5.05M | $904.00K |
| Total current liabilities | $15.66M | $17.21M | $13.30M | $6.52M |
| Long-term debt | - | - | - | - |
| Total liabilities | $17.20M | $19.80M | $17.07M | $10.75M |
| Retained earnings | -$274.88M | -$196.98M | -$116.42M | -$56.03M |
| Total equity | $112.52M | $176.79M | $121.19M | $170.47M |